还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

: D6 e& z, H. R8 |8 L请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

, V, Q  c0 a: Q( H; A4 t8 |! p可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
) Q9 T2 }: p1 c3 v. D6 G( K
! s: a0 ]2 e% k3 X" z% u# T
Sub-category:
' Y5 Y- z6 M+ x' Y6 J8 NMolecular Targets
& z* k. t# t" [5 c& v) M
/ x6 |4 d% ~5 u1 t, R
4 D' k0 A8 t' \Category:
( b4 B# d/ ~% I1 L! H/ a8 _Tumor Biology

% m) h0 \  W: P( n$ P  R
Meeting:
2011 ASCO Annual Meeting


- l$ Y, d' D9 v4 ZSession Type and Session Title:
Poster Discussion Session, Tumor Biology


6 j9 \2 p+ f& q; ?: |Abstract No:
10517
6 Y. t& M; S6 i+ w
, ~9 h/ h0 g4 ?# \5 ]3 j
# l; T: W* X/ U) V$ YCitation:
5 g" @: u) i2 D% c! P) c1 X. O% rJ Clin Oncol 29: 2011 (suppl; abstr 10517)
. c2 J7 \" r1 Y# p' k
$ i& F. G# W& w% Y% {
Author(s):
, q( Q- Y" I+ i, }1 LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
& Y4 E1 I( d8 k. x2 H0 A
. T3 T" m+ |: r2 r5 R) V$ s

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& }( Y- p9 c; j( z* Q4 Z/ @
Abstract Disclosures
- b1 |$ n/ G) r$ h% F
) u9 A4 F# N7 a( FAbstract:


Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
" W1 P9 O9 j. z! |6 }
2 [2 i9 W# k! c/ U
7 u4 ]7 r$ D$ N: J" Z* k9 o

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

* D3 p4 C" Z% Q7 L' z( _& s+ @                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

. O$ J6 ~5 k- w) k化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

3 E& p, r& O% ]) W易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

/ q) D% f. L2 P" W平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊